Vergelijking

Pasireotid vs. Terlipressin

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

396091-73-9

14636-12-5

Molecuulmassa

1047.21 g/mol

1227.37 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Terlipressin

Terlipressin is slowly converted in the body to lysine-vasopressin by cleavage of the three N-terminal glycyl residues (reservoir effect) and activates V1 receptors. The splanchnic vasoconstriction improves renal perfusion in hepatorenal syndrome.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Pasireotid	Terlipressin
Duitsland	Op recept	Op recept
Verenigde Staten	Op recept	Op recept

Volledige vermeldingen

Pasireotid

Volledige vermelding →

Terlipressin

Volledige vermelding →

Frequently asked questions

What is the difference between Pasireotid and Terlipressin?: Pasireotid is classified as "Onderzoek (overig)", while Terlipressin is classified as "Onderzoek (overig)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Terlipressin: Terlipressin is a 12-amino-acid vasopressin analog and prodrug of lysine-vasopressin. As a V1 receptor agonist it is vasoconstrictive and is approved for hepatorenal syndrome (FDA 2022, Terlivaz). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Pasireotid or Terlipressin?: The highest available evidence level is "Humane RCT" for Pasireotid and "Humane RCT" for Terlipressin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Pasireotid and Terlipressin in Germany and the United States?: Duitsland: Pasireotid — Op recept, Terlipressin — Op recept. Verenigde Staten: Pasireotid — Op recept, Terlipressin — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Pasireotid

Terlipressin

Duitsland

Op recept

Verenigde Staten

Op recept

Frequently asked questions

What is the difference between Pasireotid and Terlipressin?

Pasireotid is classified as "Onderzoek (overig)", while Terlipressin is classified as "Onderzoek (overig)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Terlipressin: Terlipressin is a 12-amino-acid vasopressin analog and prodrug of lysine-vasopressin. As a V1 receptor agonist it is vasoconstrictive and is approved for hepatorenal syndrome (FDA 2022, Terlivaz). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Pasireotid or Terlipressin?

The highest available evidence level is "Humane RCT" for Pasireotid and "Humane RCT" for Terlipressin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Pasireotid and Terlipressin in Germany and the United States?

Duitsland: Pasireotid — Op recept, Terlipressin — Op recept. Verenigde Staten: Pasireotid — Op recept, Terlipressin — Op recept. These are factual summaries with source and review date on the individual pages.